Atlantic Trust LLC Has $1.05 Million Position in Pfizer Inc. (PFE)

Atlantic Trust LLC increased its position in Pfizer Inc. (NYSE:PFE) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,906 shares of the biopharmaceutical company’s stock after buying an additional 2,653 shares during the quarter. Pfizer accounts for approximately 0.9% of Atlantic Trust LLC’s holdings, making the stock its 28th biggest holding. Atlantic Trust LLC’s holdings in Pfizer were worth $1,049,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Massachusetts Financial Services Co. MA increased its position in Pfizer by 0.3% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock valued at $2,245,053,000 after purchasing an additional 160,730 shares during the period. Morgan Stanley increased its position in Pfizer by 2.5% during the 2nd quarter. Morgan Stanley now owns 54,367,234 shares of the biopharmaceutical company’s stock valued at $1,972,442,000 after purchasing an additional 1,345,528 shares during the period. Dimensional Fund Advisors LP increased its position in Pfizer by 15.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock valued at $1,967,651,000 after purchasing an additional 7,059,171 shares during the period. Fisher Asset Management LLC increased its position in Pfizer by 4.4% during the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock valued at $1,431,069,000 after purchasing an additional 1,671,311 shares during the period. Finally, LSV Asset Management increased its position in Pfizer by 2.7% during the 2nd quarter. LSV Asset Management now owns 36,774,591 shares of the biopharmaceutical company’s stock valued at $1,334,182,000 after purchasing an additional 973,497 shares during the period. 69.42% of the stock is currently owned by institutional investors.

A number of analysts have recently weighed in on the stock. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research report on Tuesday, August 28th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Independent Research set a $48.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, October 4th. Credit Suisse Group set a $40.00 target price on shares of Pfizer and gave the stock a “hold” rating in a research report on Thursday, September 6th. Finally, Barclays reaffirmed a “neutral” rating and issued a $40.00 target price on shares of Pfizer in a research report on Wednesday, September 26th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and nine have given a buy rating to the company. Pfizer has a consensus rating of “Hold” and a consensus price target of $43.27.

In other news, major shareholder Pfizer Inc purchased 55,556 shares of the company’s stock in a transaction that occurred on Monday, October 15th. The shares were bought at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company’s stock.

Shares of Pfizer stock opened at $43.92 on Friday. The stock has a market capitalization of $268.71 billion, a P/E ratio of 16.57, a PEG ratio of 2.25 and a beta of 0.88. Pfizer Inc. has a 1 year low of $33.20 and a 1 year high of $46.47. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. The company had revenue of $13.30 billion for the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. Pfizer’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.67 EPS. As a group, analysts expect that Pfizer Inc. will post 3 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date of this dividend was Thursday, November 8th. Pfizer’s payout ratio is 51.32%.

WARNING: “Atlantic Trust LLC Has $1.05 Million Position in Pfizer Inc. (PFE)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/12/08/atlantic-trust-llc-has-1-05-million-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply